Skip to main content
SpringerLink
Log in

Alzheimer’s Disease and Other Dementias

  • Living reference work entry
  • First Online:
Geriatric Medicine

  • 166 Accesses

Abstract

Alzheimer’s disease is an abundant disorder, affecting approximately 5.5 million people in the United States alone. Alzheimer’s and other related dementias have drastic impacts on the patient, the caregiver, and society. The incidence of dementia disorders is expected to grow over the next 30 years. Given the abundance of dementia cases, high cost of care, and societal impact of disease, to name a few of the ramifications of the illness, it is prudent to have a firm understanding of the disease process so as to better help prepare patients and their caregivers. This chapter provides an overview of Alzheimer’s disease and other commonly occurring dementias with emphasis on disease screening, diagnosis, and both pharmacologic and nonpharmacologic management of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology. 2013;80(19):1778–83. https://doi.org/10.1212/WNL.0b013e31828726f5.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Kane J, Surendranathan A, Bentley A, Barker S, Taylor JP, Thomas AJ, et al. Clinical prevalence of Lewy body dementia. Alzheimers Res Ther. 2018;10(1):19. https://doi.org/10.1186/s13195-018-0350-6.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Hogan DB, Jetté N, Fiest KM, Roberts JI, Pearson D, Smith EE, et al. The prevalence and incidence of frontotemporal dementia: a systematic review. Can J Neurol Sci. 2016;43(Suppl 1):S96–109. https://doi.org/10.1017/cjn.2016.25.

    Article  PubMed  Google Scholar 

  4. Alzheimer’s Association. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement. 2020; https://doi.org/10.1002/alz.12068.

  5. Alzheimer A. Über einen eigenartigen schweren Erkrankungsprozeβ der Hirnrincle. Neurol Cent. 1906;25:1134.

    Google Scholar 

  6. Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885–90. https://doi.org/10.1016/S0006-291X(84)80190-4.

    Article  CAS  PubMed  Google Scholar 

  7. Tondelli M, Wilcock GK, Nichelli P, De Jager CA, Jenkinson M, Zamboni G. Structural MRI changes detectable up to ten years before clinical Alzheimer’s disease. Neurobiol Aging. 2012;33:825.e25–36. https://doi.org/10.1016/j.neurobiolaging.2011.05.018.

    Article  Google Scholar 

  8. Morris JC, Storandt M, McKeel DW, Rubin EH, Price JL, Grant EA, et al. Cerebral amyloid deposition and diffuse plaques in “normal” aging: evidence for presymptomatic and very mild Alzheimer’s disease. Neurology. 1996;46(3):707–19. https://doi.org/10.1212/WNL.46.3.707.

    Article  CAS  PubMed  Google Scholar 

  9. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med. 2008;14:837–42. https://doi.org/10.1038/nm1782.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Rossor MN, Iversen LL, Reynolds GP, Mountjoy CQ, Roth M. Neurochemical characteristics of early and late onset types of Alzheimer’s disease. Br Med J. 1984;288:961–4. https://doi.org/10.1136/bmj.288.6422.961.

    Article  CAS  Google Scholar 

  11. Van Oijen M, de Jong FJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Atherosclerosis and risk for dementia. Ann Neurol. 2007;61(5):403–10. https://doi.org/10.1002/ana.21073.

    Article  PubMed  Google Scholar 

  12. Caplan LR, Schoene WC. Clinical features of subcortical arteriosclerotic encephalopathy (Binswanger disease). Neurology. 1978;28(12):1206–15. https://doi.org/10.1212/WNL.28.12.1206.

    Article  CAS  PubMed  Google Scholar 

  13. Bell R, Zlokovic B. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathol. 2009;118:103–13. https://doi.org/10.1007/s00401-009-0522-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Lewy FH. Paralysis agitans. I. Pathologische Anatomie. In: Lewandowsky’s Handbuch der Neurologie, 3 Band: Spez Neurologie II. Berlin: Springer; 1912. p. 920–33.

    Google Scholar 

  15. Perry EK, Marshall E, Perry RH, Irving D, Smith CJ, Blessed G, et al. Cholinergic and dopaminergic activities in senile dementia of Lewy body type. Alzheimer Dis Assoc Disord. 1990;4(2):87–95.

    Article  CAS  PubMed  Google Scholar 

  16. Procter AW, Qurne M, Francis PT. Neurochemical features of frontotemporal dementia. Dement Geriatr Cogn Disord. 1999;10(Suppl 1):80–4. https://doi.org/10.1159/000051219.

    Article  CAS  PubMed  Google Scholar 

  17. Donix M, Small G, Bookheimer S. Family history and APOE-4 genetic risk in Alzheimer’s disease. Neuropsychol Rev. 2012;22(3):298–309. https://doi.org/10.1007/s11065-012-9193-2.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Seshadri S, Wolf PA, Beiser A, Au R, McNulty K, White R, et al. Lifetime risk of dementia and Alzheimer’s disease. The impact of mortality on risk estimates in the Framingham Study. Neurology. 1997;49(6):1498–504. https://doi.org/10.1212/wnl.49.6.1498.

    Article  CAS  PubMed  Google Scholar 

  19. Mielke M. Sex and gender differences in Alzheimer’s disease dementia. Psychiatr Times. 2018;35(11):14–7.

    PubMed  PubMed Central  Google Scholar 

  20. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240(4852):622–30. https://doi.org/10.1126/science.3283935.

    Article  CAS  PubMed  Google Scholar 

  21. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261(5123):921–3. https://doi.org/10.1126/science.8346443.

    Article  CAS  PubMed  Google Scholar 

  22. Tang M, Stern Y, Marder K, Bell K, Gurland B, Lantigua R, et al. The APOE-e4 allele and the risk of Alzheimer disease among African Americans, Whites, and Hispanics. JAMA. 1998;279(10):751–5. https://doi.org/10.1001/jama.279.10.751.

    Article  CAS  PubMed  Google Scholar 

  23. Sando SB, Melquist S, Cannon A, Hutton ML, Sletvold O, Saltvedt I, et al. APOE epsilon 4 lowers age at onset and is a high-risk factor for Alzheimer’s disease; a case control study from Central Norway. BMC Neurol. 2008;8:9. https://doi.org/10.1186/1471-2377-8-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010;23(4):213–27. https://doi.org/10.1177/0891988710383571.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Theuns J, Del-Favero J, Dermaut B, van Duijn CM, Backhovens H, Van den Broeck MV, et al. Genetic variability in the regulatory region of presenilin 1 associated with risk for Alzheimer’s disease and variable expression. Hum Mol Genet. 2000;9(3):325–31. https://doi.org/10.1093/hmg/9.3.325.

    Article  CAS  PubMed  Google Scholar 

  26. Acosta-Baena N, Sepulveda-Falla D, Lopera-Gómez CM, Jaramillo-Elorza MC, Moreno S, Aguirre-Acevedo DC, et al. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer’s disease: a retrospective cohort study. Lancet Neurol. 2011;10(3):213–20. https://doi.org/10.1016/S1474-4422(10)70323-9.

    Article  CAS  PubMed  Google Scholar 

  27. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, et al. Alzheimer’s disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 2008;7(9):812–6. https://doi.org/10.1016/S1474-4422(08)70169-8.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Samieri C, Perier MC, Gaye B, Proust-Lima C, Helmer C, Dartigues JF, et al. Association of cardiovascular health level in older age with cognitive decline and incident dementia. JAMA. 2018;320(7):657–64. https://doi.org/10.1001/jama.2018.11499.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Purnell C, Gao S, Callahan CM, Hendrie HC. Cardiovascular risk factors and incident Alzheimer disease: a systematic review of the literature. Alzheimer Dis Assoc Disord. 2009;23(1):1–10. https://doi.org/10.1097/WAD.0b013e318187541c.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ramos-Cejudo J, Wisniewski T, Marmar C, Zetterberg H, Blennow K, de Leon MJ, et al. Traumatic brain injury and Alzheimer’s disease: the cerebrovascular link. EBioMedicine. 2018;28:21–30. https://doi.org/10.1016/j.ebiom.2018.01.021.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Fann JR, Ribe AR, Pedersen HS, Fenger-Grøn M, Christensen J, Benros ME, et al. Long-term risk of dementia among people with traumatic brain injury in Denmark: a population-based observational cohort study. Lancet Psychiatry. 2018;5(5):424–31. https://doi.org/10.1016/S2215-0366(18)30065-8.

    Article  PubMed  Google Scholar 

  32. McKee AC, Stein TD, Kiernan PT, Alvarez VE. The neuropathology of chronic traumatic encephalopathy. Brain Pathol. 2015;25(3):350–64. https://doi.org/10.1111/bpa.12248.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Chodosh J, Petitti DB, Elliott M, Hays RD, Crooks VC, Reuben DB, et al. Physician recognition of cognitive impairment: evaluating the need for improvement. J Am Geriatr Soc. 2004;52(7):1051–9. https://doi.org/10.1111/j.1532-5415.2004.52301.x.

    Article  PubMed  Google Scholar 

  34. Bradford A, Kunik M, Schulz P, Williams SP, Singh H. Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis Assoc Disord. 2009;23(4):306–13. https://doi.org/10.1097/WAD.0b013e3181a6bebc.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Cordell CB, Borson S, Boustani M, Chodosh J, Reuben D, Verghese J, et al. Alzheimer’s Association recommendations for operationalizing detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. Alzheimers Dement. 2013;9(2):141–50. https://doi.org/10.1016/j.jalz.2012.09.011.

    Article  PubMed  Google Scholar 

  36. US Preventative Services Task Force. Screening for cognitive impairment in older adults. JAMA. 2020;323(8):757–63. https://doi.org/10.1001/jama.2020.0435.

    Article  Google Scholar 

  37. Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003;51(10):1451–4. https://doi.org/10.1046/j.1532-5415.2003.51465.x.

    Article  PubMed  Google Scholar 

  38. Galvin JE, Roe CM, Powlishta KK, Coats MA, Muich SJ, Grant E, et al. The AD8: a brief informant interview to detect dementia. Neurology. 2005;65(4):559–64. https://doi.org/10.1212/01.wnl.0000172958.95282.2a.

    Article  CAS  PubMed  Google Scholar 

  39. The Alzheimer’s Project Clinical Roundtable. Physician guidelines for the screening, evaluation, and management of Alzheimer’s disease and related dementias [Internet]. 2nd ed. San Diego: Champions For Health; 2018 [cited 2020 Jun 9]. Available from: https://championsforhealth.org/alzheimers-project/

  40. American Psychiatry Association. Neurocognitive disorders. In: Diagnostic and statistical manual. 5th ed. Arlington: American Psychiatric Publishing; 2013. https://doi.org/10.1176/appi.books.9780890425596.dsm17.

  41. Nasreddine Z. MoCA Montreal Cognitive Assessment [Internet]. Montreal: MoCA Test, Inc.; 2019 [cited 2020 Jun 9]. Available from: https://mocatest.org

  42. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9. https://doi.org/10.1111/j.1532-5415.2005.53221.x.

    Article  PubMed  Google Scholar 

  43. St. Louis University Medical School. VA SLUMS exam [Internet]. St. Louis: St. Louis University; 2020 [cited 2020 Jun 9]. Available from: https://www.slu.edu/medicine/internal-medicine/geriatric-medicine/aging-successfully/assessment-tools/mental-status-exam.php

  44. Tariq SH, Tumosa N, Chibnall JT, Perry MH III, Morley JE. Comparison of the Saint Louis University mental status examination and the mini-mental state examination for detecting dementia and mild neurocognitive disorder: a pilot study. Am J Geriatr Psychiatry. 2006;14(11):900–10. https://doi.org/10.1097/01.JGP.0000221510.33817.86.

    Article  PubMed  Google Scholar 

  45. Feliciano L, Horning SM, Klebe KJ, Anderson SL, Cornwell RE, Davis HP. Utility of the SLUMS as a cognitive screening tool among a nonveteran sample of older adults. Am J Geriatr Psychiatry. 2013;21(7):623–30. https://doi.org/10.1016/j.jagp.2013.01.024.

    Article  PubMed  Google Scholar 

  46. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1143–53. https://doi.org/10.1212/WNL.56.9.1143.

    Article  CAS  PubMed  Google Scholar 

  47. Harvard School of Public Health and Alzheimer’s Europe. Value of knowing [Internet]; 2013 [updated 2014 Nov 14; cited 2020 Jun 9]. Available at: https://www.alzheimer-europe.org/Research/Value-of-Knowing#_edn2

  48. Gergerich EM. Reporting policy regarding drivers with dementia. Gerontologist. 2016;56(2):345–56. https://doi.org/10.1093/geront/gnv143.

    Article  PubMed  Google Scholar 

  49. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet. 2004;363(9427):2105–15. https://doi.org/10.1016/S0140-6736(04)16499-4.

    Article  CAS  Google Scholar 

  50. Tricco AC, Ashoor HM, Soobiah C, Rios P, Veroniki AA, Hamid JS, et al. Comparative effectiveness and safety of cognitive enhancers for treating Alzheimer’s disease: systematic review and network metaanalysis. J Am Geriatr Soc. 2018;66(1):170–8. https://doi.org/10.1111/jgs.15069.

    Article  PubMed  Google Scholar 

  51. Choosing Wisely. Don’t prescribe cholinesterase inhibitors for dementia without periodic assessment for perceived cognitive benefits and adverse gastrointestinal effects [Internet]. Philadelphia: ABIM Foundation; 2014 [updated 2015 Apr 23; cited 2020 Jun 9]. Available at: https://www.choosingwisely.org/clinician-lists/american-geriatrics-society-cholinesterase-inhibitors-for-dementia/

  52. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012;366(10):893–903. https://doi.org/10.1056/NEJMoa1106668.

    Article  CAS  PubMed  Google Scholar 

  53. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148(5):379–97. https://doi.org/10.7326/0003-4819-148-5-200803040-00009.

    Article  PubMed  Google Scholar 

  54. Farina N, Llewellyn D, Isaac MGEKN, Tabet N. Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2017;4(4):CD002854. https://doi.org/10.1002/14651858.CD002854.pub5.

    Article  PubMed  Google Scholar 

  55. Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014;311(1):33–44. https://doi.org/10.1001/jama.2013.282834.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37–46. https://doi.org/10.7326/0003-4819-142-1-200501040-00110.

    Article  CAS  PubMed  Google Scholar 

  57. Birks J, Evans JG. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2009;2009(1):CD003120. https://doi.org/10.1002/14651858.CD003120.pub3.

    Article  Google Scholar 

  58. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzuamb in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):322–33. https://doi.org/10.1056/NEJMoa1304839.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):311–21. https://doi.org/10.1056/NEJMoa1312889.

    Article  CAS  PubMed  Google Scholar 

  60. Budd-Haeberlein S, et al. EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer’s disease. Clinical trials on Alzheimer’s disease conference. 2019.

    Google Scholar 

  61. Hollmann P, Lundebjerg N. American Geriatrics Society letter. Re: food and drug administration’s review of Biogen’s drug aducaumab for Alzheimer’s disease. 2021. https://www.americangeriatrics.org/sites/default/files/inline-files/American%20Geriatrics%20Society_Letter%20to%20FDA%20Biogen%20Drug%20for%20Alzheimer%27s%20%28June%202021%29%20FINAL%20%281%29.pdf

  62. von Hehn C, von Rosenstiel P, Tian Y, Wu S, Chen T, Skordos L, Harrison K, et al. Baseline characteristics from ENGAGE and EMERGE: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer’s disease. Neurology. 2019;92(Suppl 15):P4.1-001.

    Google Scholar 

  63. Groot C, Hooghiemstra AM, Raijmakers PG, et al. The effect of physical activity on cognitive function in patients with dementia: a meta-analysis of randomized control trials. Ageing Res Rev. 2016;25:13–23. https://doi.org/10.1016/j.arr.2015.11.005.

    Article  CAS  PubMed  Google Scholar 

  64. Farina N, Rusted J, Tabet N. The effect of exercise interventions on cognitive outcome in Alzheimer’s disease: a systematic review. Int Psychogeriatr. 2014;26(1):9–18. https://doi.org/10.1017/S1041610213001385.

    Article  PubMed  Google Scholar 

  65. Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S. Exercise programs for people with dementia. Cochrane Database Syst Rev. 2015;2015(4):CD006489. https://doi.org/10.1002/14651858.CD006489.pub4.

    Article  PubMed Central  Google Scholar 

  66. Bahar-Fuchs A, Martyr A, Goh AM, Sabates J, Clare L. Cognitive training for people with mild to moderate dementia. Cochrane Database Syst Rev. 2019;3(3):CD013069. https://doi.org/10.1002/14651858.CD013069.pub2.

    Article  PubMed  Google Scholar 

  67. Saczynski JS, Pfeifer LA, Masaki K, Korf ESC, Laurin D, White L, et al. The effect of social engagement on incident dementia: the Honolulu-Asia Aging Study. Am J Epidemiol. 2006;163(5):433–40. https://doi.org/10.1093/aje/kwj061.

    Article  PubMed  Google Scholar 

  68. Beeri MS, Werner P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer’s disease patients. Int J Geriatr Psychiatry. 2002;17(5):403–8. https://doi.org/10.1002/gps.490.

    Article  PubMed  Google Scholar 

  69. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer’s disease: a natural history study. J Am Geriatr Soc. 1996;44(9):1078–81. https://doi.org/10.1111/j.1532-5415.1996.tb02942.x.

    Article  CAS  PubMed  Google Scholar 

  70. Flacker J, Cummings V, Mach JR Jr, Bettin K, Kiely DK, Wei J. The association of serum anticholinergic activity with delirium in elderly patients. Am J Geriatr Psychiatry. 1998;6(1):31–41. https://doi.org/10.1097/00019442-199802000-00005.

    Article  CAS  PubMed  Google Scholar 

  71. Femia EE, Zarit SH, Stephens MAP, Greene R. Impact of adult day services on behavioral and psychological symptoms of dementia. Gerontologist. 2007;47(6):775–88. https://doi.org/10.1093/geront/47.6.775.

    Article  PubMed  Google Scholar 

  72. Alzheimer’s Association. Caregiving [Internet]. Chicago: Alzheimer’s Association; 2020 [cited 2020 Jun 9]. Available at: https://alz.org/help-support/caregiving

  73. Volicer L, Hurley AC. Management of behavioral symptoms in progressive degenerative dementias. J Gerontol A Biol Sci Med Sci. 2003;58(9):M837–45. https://doi.org/10.1093/Gerona/58.9.M837.

    Article  PubMed  Google Scholar 

  74. Goldman JS, Hahn SE, Catania JW, LaRusse-Eckert S, Butson MB, Rumbaugh M, et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med. 2012;13(6):597–605. https://doi.org/10.1097/GIM.0b013e31821d69b8.

    Article  Google Scholar 

  75. Kramer SI, Reifler BV. Depression, dementia, and reversible dementia. Clin Geriatr Med. 1992;8(2):289–97.

    Article  CAS  PubMed  Google Scholar 

  76. Kang KM, Sohn CH, Byun MS, Lee JH, Yi D, Lee Y, … KBASE Research Group. Prediction of amyloid positivity in mild cognitive impairment using fully automated brain segmentation software. Neuropsychiatr Dis Treat. 2020;16:1745–54. https://doi.org/10.2147/NDT.S252293.

Download references

Author information

Authors and Affiliations

  1. Geriatrics, Gerontology, and Palliative Care, UC San Diego Health, San Diego, CA, USA

    Ian Curtis Neel

Authors
  1. Ian Curtis Neel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian Curtis Neel .

Editor information

Editors and Affiliations

  1. Rockport Healthcare Services, Woodland Hills, CA, USA

    Michael Wasserman

  2. Betty Irene Moore School of Nursing, University of California, Davis, Sacramento, CA, USA

    Debra Bakerjian

  3. Department of Clinical Pharmacy, University of Colorado, Aurora, CO, USA

    Sunny Linnebur

  4. Division of Geriatrics, SUNY Upstate Medical University, Syracuse, NY, USA

    Sharon Brangman

  5. Alliant GMCF, Atlanta, GA, USA

    Adrienne Mims

  6. Division of Geriatric Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Jerry C. Johnson

Section Editor information

  1. Department of Clinical Pharmacy, University of Colorado School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA

    Sunny Linnebur PharmD

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Neel, I.C. (2023). Alzheimer’s Disease and Other Dementias. In: Wasserman, M., Bakerjian, D., Linnebur, S., Brangman, S., Mims, A., Johnson, J.C. (eds) Geriatric Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-01782-8_84-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-01782-8_84-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-01782-8

  • Online ISBN: 978-3-030-01782-8

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation